Floatz logo

Mage-A1-Specific T Cell Receptor-Transduced Autologous T-Cells

Metastatic Urothelial Carcinoma

Fred Hutchinson Cancer CenterCell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

167 Active assets in the Metastatic Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB

View all 50 →

Same molecule, other indications

Mage-A1-Specific T Cell Receptor-Transduced Autologous T-Cells is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
breast cancerDormant
CC
Indicative ·
45 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →